Close Menu
Home » Myriad RBM, Sanofi Partner to Identify CV Biomarkers in Diabetes Patients

Myriad RBM, Sanofi Partner to Identify CV Biomarkers in Diabetes Patients

Oct 25, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Myriad RBM announced today that it has signed an agreement to help Sanofi measure cardiovascular risk biomarkers in the blood samples of patients in a Phase III trial of its type II diabetes therapy lixisenatide.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Project to Discuss Race and Genetics in Class

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

Taking It All On

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

PLOS Papers on ASD-Related Syndrome, Twin Gut Microbiomes, Zika Virus Evolution

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

Unexpected Close

GenomeWeb reports that Veritas Genetics is suspending its US operations.

What's Popular?

In Business News

  1. Roche Ending Partnership With Syapse

  2. Veritas Genetics Halts US Operations, Lays Off More Than 30

  3. Biocept Prices $10M Public Offering of Stocks, Warrants

  4. Illumina, PacBio Dispute UK Regulator's Finding That Merger Would Weaken Competition

  5. Veracyte Pursues International Expansion With Global License Agreement

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.